Stock Scorecard
Stock Summary for Alaunos Therapeutics Inc (TCRT) - $4.00 as of 6/19/2025 11:32:12 AM EST
Total Score
6 out of 30
Safety Score
18 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TCRT
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TCRT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TCRT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TCRT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for TCRT (18 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 0 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 3 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for TCRT
Financial Details for TCRT
Company Overview |
|
|---|---|
| Ticker | TCRT |
| Company Name | Alaunos Therapeutics Inc |
| Country | USA |
| Description | Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 4.00 |
| Price 4 Years Ago | 163.50 |
| Last Day Price Updated | 6/19/2025 11:32:12 AM EST |
| Last Day Volume | 77,484 |
| Average Daily Volume | 27,910 |
| 52-Week High | 7.72 |
| 52-Week Low | 1.31 |
| Last Price to 52 Week Low | 205.34% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.19 |
| Sector PE | 40.43 |
| 5-Year Average PE | -200.64 |
| Free Cash Flow Ratio | 21.05 |
| Industry Free Cash Flow Ratio | 17.31 |
| Sector Free Cash Flow Ratio | 31.51 |
| Current Ratio Most Recent Quarter | 1.00 |
| Total Cash Per Share | 0.19 |
| Book Value Per Share Most Recent Quarter | 0.66 |
| Price to Book Ratio | 6.19 |
| Industry Price to Book Ratio | 34.28 |
| Sector Price to Book Ratio | 30.07 |
| Price to Sales Ratio Twelve Trailing Months | 595.59 |
| Industry Price to Sales Ratio Twelve Trailing Months | 121.20 |
| Sector Price to Sales Ratio Twelve Trailing Months | 34.41 |
| Analyst Buy Ratings | N/A |
| Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
| Total Shares Outstanding | 1,639,500 |
| Market Capitalization | 6,558,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 1.36% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 86.68% |
| Reported EPS 12 Trailing Months | -2.54 |
| Reported EPS Past Year | -0.67 |
| Reported EPS Prior Year | -2.36 |
| Net Income Twelve Trailing Months | -4,071,000 |
| Net Income Past Year | -4,679,000 |
| Net Income Prior Year | -35,140,000 |
| Quarterly Revenue Growth YOY | 100.00% |
| 5-Year Revenue Growth | -49.08% |
| Operating Margin Twelve Trailing Months | -54,600.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 319,000 |
| Total Cash Past Year | 1,091,000 |
| Total Cash Prior Year | 6,062,000 |
| Net Cash Position Most Recent Quarter | 319,000 |
| Net Cash Position Past Year | -15,674,000 |
| Long Term Debt Past Year | 16,765,000 |
| Long Term Debt Prior Year | 16,765,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.11 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 2,063,000 |
| Total Stockholder Equity Prior Year | 6,307,000 |
| Total Stockholder Equity Most Recent Quarter | 1,058,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 19,111,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 11.66 |
| Free Cash Flow Past Year | -4,971,000 |
| Free Cash Flow Prior Year | -30,339,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.17 |
| MACD Signal | 0.10 |
| 20-Day Bollinger Lower Band | 0.92 |
| 20-Day Bollinger Middle Band | 2.35 |
| 20-Day Bollinger Upper Band | 3.77 |
| Beta | -1.09 |
| RSI | 71.12 |
| 50-Day SMA | 56.32 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 84.09 |
System |
|
| Modified | 6/19/2025 11:32:14 AM EST |